Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis.

We compared the efficacy and the long-term effects of nocturnal hemodialysis (NHD) versus conventional hemodialysis (CHD) in controlling serum phosphate levels in patients with end-stage renal disease (ESRD). Patients underwent thrice weekly CHD and were subsequently switched to NHD six nights weekly. In the "acute" study serum and dialysate phosphate were measured during and after dialysis, and the total dialysate was collected to calculate mass solute removal. Although pre-dialysis (1.7 +/- 0.6 vs. 1.5 +/- 0.8 mM) serum phosphate levels were similar in CHD and NHD, respectively, post-dialysis levels were slightly lower with CHD (0.7 +/- 0.2 vs. 0.8 +/- 0.2 mM, P < 0.05). The measured phosphate removed per session of CHD or NHD was comparable, 25.3 +/- 7.5 versus 26.9 +/- 9.8 mumol/session, respectively. On the other hand, the cumulative weekly phosphate removal was significantly higher with NHD as compared to CHD, 75.8 +/- 22.5 versus 161.6 +/- 59.0 mumol/week (P < 0.01). In the "chronic" study serum phosphate levels were measured monthly for five months on CHD and for five months after the patients were switched to NHD. Dietary phosphate intake and the dosage of phosphate binders were tabulated. Serum phosphate levels fell during NHD: 2.1 +/- 0.5 mM at the beginning of the study and 1.3 +/- 0.2 mM five months after being switched to NHD (P < 0.001). At the same time dietary phosphate intake increased by 50%. By the fourth month of NHD therapy none of the patients was taking any phosphate binders. In conclusion, NHD is more effective in controlling serum phosphate levels than CHD, allowing patients to discontinue their phosphate binders completely and to ingest a more liberal diet.

[1]  P. Chauveau,et al.  Phosphate removal rate: a comparative study of five high-flux dialysers. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  R. Uldall,et al.  A new vascular access catheter for hemodialysis. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  G. Gomori.  A modification of the colorimetric phosphorus determination for use with the photoelectric colorimeter. , 1942 .

[4]  J. Kopple,et al.  Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. , 1982, Kidney international.

[5]  J. Fordtran,et al.  The absorption of dietary phosphorus and calcium in hemodialysis patients. , 1986, Kidney international.

[6]  J. Delmez,et al.  Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Y. Pei,et al.  The spectrum of bone disease in end-stage renal failure--an evolving disorder. , 1993, Kidney international.

[8]  Mei Wang,et al.  Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  I. Mucsi,et al.  Adynamic bone disease: pathogenesis, diagnosis and clinical relevance , 1997, Current opinion in nephrology and hypertension.

[10]  W. D. Kaehny,et al.  The dialysis encephalopathy syndrome. Possible aluminum intoxication. , 1976, The New England journal of medicine.

[11]  J. Coburn,et al.  Control of Hyperphosphatemia in Chronic Renal Failure , 1990 .

[12]  V. Pinn,et al.  Immune complex glomerulonephritis in hydralazine-induced SLE. , 1984, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  R Francoeur,et al.  Nocturnal hemodialysis: three-year experience. , 1998, Journal of the American Society of Nephrology : JASN.

[14]  T. Haas,et al.  Phosphate kinetics in dialysis patients. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  W. Hörl,et al.  Disturbed calcium metabolism in renal failure--pathogenesis and therapeutic strategies. , 1992, Kidney international. Supplement.

[16]  J. Delmez,et al.  Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. , 1986, The New England journal of medicine.

[17]  P Zucchelli,et al.  Inorganic Phosphate Removal during Different Dialytic Procedures , 1987, The International journal of artificial organs.

[18]  H. Holzer,et al.  Phosphorus kinetics during haemodialysis and haemofiltration. , 1985, Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress.

[19]  K. Schaefer.  Alternative phosphate binders: an update. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  J. Bourdeau,et al.  Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  J. Shinaberger,et al.  High-flux hemodiafiltration: under six hours/week treatment. , 1984, Transactions - American Society for Artificial Internal Organs.

[22]  J. Coburn,et al.  Prevention of phosphate retention and hyperphosphatemia in uremia. , 1987, Kidney international. Supplement.

[23]  G. Berlyne,et al.  Hyperaluminaemia from aluminum resins in renal failure. , 1970, Lancet.

[24]  D. Sherrard,et al.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. , 1993, Kidney international.

[25]  J. Kopple,et al.  METABOLIC STUDIES OF LOW PROTEIN DIETS IN UREMIA: II. CALCIUM, PHOSPHOKUS AND MAGNESIUM , 1973, Medicine.

[26]  F. A. Schofield,et al.  Calcium, phosphorus and magnesium. , 1960, Federation proceedings.

[27]  G. Manente,et al.  Solute kinetics in hypertonic hemodiafiltration and standard hemodialysis. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  U. Simeoni,et al.  Phosphate dialytic removal: enhancement of phosphate cellular clearance by biofiltration (with acetate-free buffer dialysate). , 1992, Nephron.